These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
120 related articles for article (PubMed ID: 27465946)
1. [Value of a two-step approach with cytokeratin-18 and controlled attenuation parameter in noninvasive differential diagnosis of nonalcoholic steatohepatitis]. Shen F; Zheng RD; Mi YQ; Shi JP; Wang XY; Hu XQ; Pan Q; Xu LM; Fan JG Zhonghua Gan Zang Bing Za Zhi; 2016 Jun; 24(6):429-34. PubMed ID: 27465946 [TBL] [Abstract][Full Text] [Related]
2. Serum cytokeratin-18 fragment levels as noninvasive marker of nonalcoholic steatohepatitis in the chilean population. Arab JP; Hernández-Rocha C; Morales C; Vargas JI; Solís N; Pizarro M; Robles C; Sandoval D; Ponthus S; Benítez C; Barrera F; Soza A; Riquelme A; Arrese M Gastroenterol Hepatol; 2017; 40(6):388-394. PubMed ID: 28359548 [TBL] [Abstract][Full Text] [Related]
4. Assessment of non-alcoholic fatty liver disease using serum total cell death and apoptosis markers. Shen J; Chan HL; Wong GL; Chan AW; Choi PC; Chan HY; Chim AM; Yeung DK; Yu J; Chu WC; Wong VW Aliment Pharmacol Ther; 2012 Dec; 36(11-12):1057-66. PubMed ID: 23066946 [TBL] [Abstract][Full Text] [Related]
5. [Value of serum osteoprotegerin in noninvasive diagnosis of nonalcoholic steatohepatitis]. Yang M; Liu Y; Zhou G; Guo X; Zou S; Liu S; Jiang L; Liu Y; Zhu L; Guo C; Zhao J Zhonghua Gan Zang Bing Za Zhi; 2016 Feb; 24(2):96-101. PubMed ID: 26983475 [TBL] [Abstract][Full Text] [Related]
6. Correlation between serum cytokeratin-18 and the progression or regression of non-alcoholic fatty liver disease. Kawanaka M; Nishino K; Nakamura J; Urata N; Oka T; Goto D; Suehiro M; Kawamoto H; Yamada G Ann Hepatol; 2015; 14(6):837-44. PubMed ID: 26436355 [TBL] [Abstract][Full Text] [Related]
7. Diagnostic Value of CK-18, FGF-21, and Related Biomarker Panel in Nonalcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis. He L; Deng L; Zhang Q; Guo J; Zhou J; Song W; Yuan F Biomed Res Int; 2017; 2017():9729107. PubMed ID: 28326329 [TBL] [Abstract][Full Text] [Related]
8. A Noninvasive Score Model for Prediction of NASH in Patients with Chronic Hepatitis B and Nonalcoholic Fatty Liver Disease. Liang J; Liu F; Wang F; Han T; Jing L; Ma Z; Gao Y Biomed Res Int; 2017; 2017():8793278. PubMed ID: 28349067 [No Abstract] [Full Text] [Related]
9. [Value of controlled attenuation parameter in diagnosis of fatty liver using FibroScan]. Xu L; Li P; Lu W; Shi Q; Shi R; Zhang X; Liu Y; Wang Q; Fan J; Mi Y Zhonghua Gan Zang Bing Za Zhi; 2016 Feb; 24(2):108-13. PubMed ID: 26983477 [TBL] [Abstract][Full Text] [Related]
10. Soluble forms of extracellular cytokeratin 18 may differentiate simple steatosis from nonalcoholic steatohepatitis. Yilmaz Y; Dolar E; Ulukaya E; Akgoz S; Keskin M; Kiyici M; Aker S; Yilmaztepe A; Gurel S; Gulten M; Nak SG World J Gastroenterol; 2007 Feb; 13(6):837-44. PubMed ID: 17352011 [TBL] [Abstract][Full Text] [Related]
11. Combined Serum Biomarkers in Non-Invasive Diagnosis of Non-Alcoholic Steatohepatitis. Yang M; Xu D; Liu Y; Guo X; Li W; Guo C; Zhang H; Gao Y; Mao Y; Zhao J PLoS One; 2015; 10(6):e0131664. PubMed ID: 26121037 [TBL] [Abstract][Full Text] [Related]
12. Poor Inter-test Reliability Between CK18 Kits as a Biomarker of NASH. Pimentel CF; Jiang ZG; Otsubo T; Feldbrügge L; Challies TL; Nasser I; Robson S; Afdhal N; Lai M Dig Dis Sci; 2016 Mar; 61(3):905-12. PubMed ID: 26462489 [TBL] [Abstract][Full Text] [Related]
13. A novel diagnostic biomarker panel for obesity-related nonalcoholic steatohepatitis (NASH). Younossi ZM; Jarrar M; Nugent C; Randhawa M; Afendy M; Stepanova M; Rafiq N; Goodman Z; Chandhoke V; Baranova A Obes Surg; 2008 Nov; 18(11):1430-7. PubMed ID: 18500507 [TBL] [Abstract][Full Text] [Related]
14. Noninvasive clinical model for the diagnosis of nonalcoholic steatohepatitis in overweight and morbidly obese patients undergoing bariatric surgery. Pirvulescu I; Gheorghe L; Csiki I; Becheanu G; Dumbravă M; Fica S; Martin S; Sarbu A; Gheorghe C; Diculescu M; Copăescu C Chirurgia (Bucur); 2012; 107(6):772-9. PubMed ID: 23294957 [TBL] [Abstract][Full Text] [Related]
15. Cytokeratin 18 fragment levels as a noninvasive biomarker for nonalcoholic steatohepatitis in bariatric surgery patients. Diab DL; Yerian L; Schauer P; Kashyap SR; Lopez R; Hazen SL; Feldstein AE Clin Gastroenterol Hepatol; 2008 Nov; 6(11):1249-54. PubMed ID: 18995215 [TBL] [Abstract][Full Text] [Related]
16. Usefulness of the index of NASH - ION for the diagnosis of steatohepatitis in patients with non-alcoholic fatty liver: An external validation study. Younes R; Rosso C; Petta S; Cucco M; Marietti M; Caviglia GP; Ciancio A; Abate ML; Cammà C; Smedile A; Craxì A; Saracco GM; Bugianesi E Liver Int; 2018 Apr; 38(4):715-723. PubMed ID: 29028281 [TBL] [Abstract][Full Text] [Related]
17. New scoring system combining the FIB-4 index and cytokeratin-18 fragments for predicting steatohepatitis and liver fibrosis in patients with nonalcoholic fatty liver disease. Tada T; Kumada T; Toyoda H; Saibara T; Ono M; Kage M Biomarkers; 2018; 23(4):328-334. PubMed ID: 29308929 [TBL] [Abstract][Full Text] [Related]
18. A Bayesian approach to an integrated multimodal noninvasive diagnosis of definitive nonalcoholic steatohepatitis in the spectrum of nonalcoholic fatty liver disease. Yilmaz Y; Eren F Eur J Gastroenterol Hepatol; 2014 Nov; 26(11):1292-5. PubMed ID: 25171027 [TBL] [Abstract][Full Text] [Related]
19. Diagnostic and prognostic significance of cell death and macrophage activation markers in patients with hepatocellular carcinoma. Waidmann O; Köberle V; Bettinger D; Trojan J; Zeuzem S; Schultheiß M; Kronenberger B; Piiper A J Hepatol; 2013 Oct; 59(4):769-79. PubMed ID: 23792028 [TBL] [Abstract][Full Text] [Related]